<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Pediatrics - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcpediatr/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Pediatrics (ISSN 1471-2431) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/3/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/7/24"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/14"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/23"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/24"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/7/36"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/17"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/16"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/20"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/13">
            
            <title>Kangaroo mother care diminishes pain from heel lance in very preterm neonates: A crossover trial</title>
			<description>Background:
Skin-to-skin contact, or kangaroo mother care (KMC) has been shown to be efficacious in diminishing pain response to heel lance in full term and moderately preterm neonates. The purpose of this study was to determine if KMC would also be efficacious in very preterm neonates.
Methods:
Preterm neonates (n = 61) between 28 0/7 and 31 6/7 weeks gestational age in three Level III NICU's in Canada comprised the sample. A single-blind randomized crossover design was employed. In the experimental condition, the infant was held in KMC for 15 minutes prior to and throughout heel lance procedure. In the control condition, the infant was in prone position swaddled in a blanket in the incubator. The primary outcome was the Premature Infant Pain Profile (PIPP), which is comprised of three facial actions, maximum heart rate, minimum oxygen saturation levels from baseline in 30-second blocks from heel lance. The secondary outcome was time to recover, defined as heart rate return to baseline. Continuous video, heart rate and oxygen saturation monitoring were recorded with event markers during the procedure and were subsequently analyzed. Repeated measures analysis-of-variance was employed to generate results.
Results:
PIPP scores at 90 seconds post lance were significantly lower in the KMC condition (8.871 (95%CI 7.852&#8211;9.889) versus 10.677 (95%CI 9.563&#8211;11.792) p &lt; .001) and non-significant mean differences ranging from 1.2 to1.8. favoring KMC condition at 30, 60 and 120 seconds. Time to recovery was significantly shorter, by a minute(123 seconds (95%CI 103&#8211;142) versus 193 seconds (95%CI 158&#8211;227). Facial actions were highly significantly lower across all points in time reaching a two-fold difference by 120 seconds post-lance and heart rate was significantly lower across the first 90 seconds in the KMC condition.
Conclusion:
Very preterm neonates appear to have endogenous mechanisms elicited through skin-to-skin maternal contact that decrease pain response, but not as powerfully as in older preterm neonates. The shorter recovery time in KMC is clinically important in helping maintain homeostasis.Trial Registration(Current Controlled Trials) ISRCTN63551708</description>
			<link>http://www.biomedcentral.com/1471-2431/8/13</link>		
			<dc:creator>C Celeste Johnston, Francoise Filion, Marsha Campbell-Yeo, Celine Goulet, Linda Bell, Kathryn McNaughton, Jasmine Byron, Marilyn Aita, G Allen Finley and Claire-Dominique Walker</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:13</dc:source>
			<dc:subject>Number of accesses: 5488</dc:subject>
			<dc:date>2008-04-24</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/3/13">
            
            <title>A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format</title>
			<description>Background:
The Babson and Benda 1976 "fetal-infant growth graph" for preterm infants is commonly used in neonatal intensive care. Its limits include the small sample size which provides low confidence in the extremes of the data, the 26 weeks start and the 500 gram graph increments. The purpose of this study was to develop an updated growth chart beginning at 22 weeks based on a meta-analysis of published reference studies.
Methods:
The literature was searched from 1980 to 2002 for more recent data to complete the pre and post term sections of the chart. Data were selected from population studies with large sample sizes. Comparisons were made between the new chart and the Babson and Benda graph. To validate the growth chart the growth results from the National Institute of Child Health and Human Development Neonatal Research Network (NICHD) were superimposed on the new chart.
Results:
The new data produced curves that generally followed patterns similar to the old growth graph. Mean differences between the curves of the two charts reached statistical significance after term. Babson's 10th percentiles fell between the new data percentiles: the 5th to 17th for weight, the 5th and 15th for head circumference, and the 6th and 16th for length. The growth patterns of the NICHD infants deviated away from the curves of the chart in the first weeks after birth. When the infants reached an average weight of 2 kilograms, those with a birthweight in the range of 700 to 1000 grams had achieved greater than the 10th percentile on average for head growth, but remained below the 3rd percentile for weight and length.
Conclusion:
The updated growth chart allows a comparison of an infant's growth first with the fetus as early as 22 weeks and then with the term infant to 10 weeks. Comparison of the size of the NICHD infants at a weight of 2 kilograms provides evidence that on average preterm infants are growth retarded with respect to weight and length while their head size has caught up to birth percentiles. As with all meta-analyses, the validity of this growth chart is limited by the heterogeneity of the data sources. Further validation is needed to illustrate the growth patterns of preterm infants to older ages.</description>
			<link>http://www.biomedcentral.com/1471-2431/3/13</link>		
			<dc:creator>Tanis R Fenton</dc:creator>
			<dc:source>BMC Pediatrics 2003, 3:13</dc:source>
			<dc:subject>Number of accesses: 2182</dc:subject>
			<dc:date>2003-12-16</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-3-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2003-12-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/7/24">
            
            <title>Leukocyte counts in urine reflect the risk of concomitant sepsis in bacteriuric infants: A retrospective cohort study</title>
			<description>Background:
When urine infections are missed in febrile young infants with normal urinalysis, clinicians may worry about the risk &#8211; hitherto unverified &#8211; of concomitant invasion of blood and cerebrospinal fluid by uropathogens. In this study, we determine the extent of this risk.
Methods:
In a retrospective cohort study of febrile 0&#8211;89 day old infants evaluated for sepsis in an urban academic pediatric emergency department (1993&#8211;1999), we estimated rates of bacteriuric sepsis (urinary tract infections complicated by sepsis) after stratifying infants by urine leukocyte counts higher, or lower than 10 cells/hpf. We compared the global accuracy of leukocytes in urine, leukocytes in peripheral blood, body temperature, and age for predicting bacteruric sepsis. The global accuracy of each test was estimated by calculating the area under its receiver operating characteristic curve (AUC). Chi-square and Fisher exact tests compared count data. Medians for data not normally distributed were compared by the Kruskal-Wallis test.
Results:
Two thousand two hundred forty-nine young infants had a normal screening dipstick. None of these developed bacteremia or meningitis despite positive urine culture in 41 (1.8%). Of 1516 additional urine specimens sent for formal urinalysis, 1279 had 0&#8211;9 leukocytes/hpf. Urine pathogens were isolated less commonly (6% vs. 76%) and at lower concentrations in infants with few, compared to many urine leukocytes. Urine leukocytes (AUC: 0.94) were the most accurate predictors of bacteruric sepsis. Infants with urinary leukocytes &lt; 10 cells/hpf were significantly less likely (0%; CI:0&#8211;0.3%) than those with higher leukocyte counts (5%; CI:2.6&#8211;8.7%) to have urinary tract infections complicated by bacteremia (N = 11) or bacterial meningitis (N = 1) &#8211; relative risk, 0 (CI:0&#8211;0.06) [RR, 0 (CI: 0&#8211;0.02), when including infants with negative dipstick]. Bands in peripheral blood had modest value for detecting bacteriuric sepsis (AUC: 0.78). Cases of sepsis without concomitant bacteriuria were comparatively rare (0.8%) and equally common in febrile young infants with low and high concentrations of urine leukocytes.
Conclusion:
In young infants evaluated for fever, leukocytes in urine reflect the likelihood of bacteriuric sepsis. Infants with urinary tract infections missed because of few leukocytes in urine are at relatively low risk of invasive bacterial sepsis by pathogens isolated from urine.</description>
			<link>http://www.biomedcentral.com/1471-2431/7/24</link>		
			<dc:creator>Bema K Bonsu and Marvin B Harper</dc:creator>
			<dc:source>BMC Pediatrics 2007, 7:24</dc:source>
			<dc:subject>Number of accesses: 623</dc:subject>
			<dc:date>2007-06-13</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-7-24</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-06-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/14">
            
            <title>Effectiveness of physical therapy interventions for children with cerebral palsy: A systematic review</title>
			<description>Background:
To assess the effectiveness of physical therapy (PT) interventions on functioning in children with cerebral palsy (CP).
Methods:
A search was made in Medline, Cinahl, PEDro and the Cochrane library for the period 1990 to February 2007. Only randomized controlled trials (RCTs) on PT interventions in children with diagnosed CP were included. Two reviewers independently assessed the methodological quality and extracted the data. The outcomes measured in the trials were classified using the International Classification of Functioning, Disability and Health (ICF).
Results:
Twenty-two trials were identified. Eight intervention categories were distinguished. Four trials were of high methodological quality. Moderate evidence of effectiveness was established for two intervention categories: effectiveness of upper extremity treatments on attained goals and active supination, and of prehensile hand treatment and neurodevelopmental therapy (NDT) or NDT twice a week on developmental status, and of constraint-induced therapy on amount and quality of hand use. Moderate evidence of ineffectiveness was found of strength training on walking speed and stride length. Conflicting evidence was found for strength training on gross motor function. For the other intervention categories the evidence was limited due to low methodological quality and the statistically insignificant results of the studies.
Conclusion:
Due to limitations in methodological quality and variations in population, interventions and outcomes, mostly limited evidence on the effectiveness of most PT interventions is available through RCTs. Moderate evidence was found for some effectiveness of upper extremity training. Well-designed trials are needed especially for focused PT interventions.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/14</link>		
			<dc:creator>Heidi Anttila, Ilona Autti-R&#228;m&#246;, Jutta Suoranta, Marjukka M&#228;kel&#228; and Antti Malmivaara</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:14</dc:source>
			<dc:subject>Number of accesses: 546</dc:subject>
			<dc:date>2008-04-24</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-14</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/23">
            
            <title>Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial</title>
			<description>Background:
For children at high risk of chronic suppurative otitis media (CSOM), strategies to prevent acute otitis media with perforation (AOMwiP) may reduce progression to CSOM.
Methods:
In a double blind study in northern Australia, 103 Aboriginal infants with first detection of OME were randomised to receive either amoxicillin (50 mg/kg/d BD) or placebo for 24 weeks, or until bilateral aerated middle ears were diagnosed at two successive monthly examinations (success). Standardised clinical assessments and international standards for microbiology were used.
Results:
Five of 52 infants in the amoxicillin group and none of 51 infants in the placebo group achieved success at the end of therapy (Risk Difference = 9.6% [95% confidence interval 1.6,17.6]). Amoxicillin significantly reduced the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2]), and iii) reduced the proportion of examinations with a diagnosis of perforation during therapy (20% to 8% adjusted risk ratio 0.36 [0.15,0.83] p = 0.017). During therapy, the proportion of examinations with penicillin non-susceptible (MIC > 0.1 microg/ml) pneumococci was not significantly different between the amoxicillin group (34%) and the placebo group (40%). Beta-lactamase positive non-capsular H. influenzae (NCHi) were uncommon during therapy but more frequent in the amoxicillin group (10%) than placebo (5%).
Conclusion:
Aboriginal infants receiving continuous amoxicillin had more normal ears, fewer perforations, and less pneumococcal carriage. There was no statistically significant increase in resistant pneumococci or NCHi in amoxicillin children compared to placebo children who received regular paediatric care and antibiotic treatment for symptomatic illnesses.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/23</link>		
			<dc:creator>Amanda J Leach, Peter S Morris, John D Mathews and the Chronic Otitis Media Intervention Trial &#8211; One (COMIT1) group</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:23</dc:source>
			<dc:subject>Number of accesses: 529</dc:subject>
			<dc:date>2008-06-02</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-23</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/24">
            
            <title>Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks</title>
			<description>Background:
Changes and relationships of components of the cytokine and IGF systems have been shown in placenta and cord serum of fetal growth restricted (FGR) compared with normal newborns (AGA). This study aimed to analyse a data set of clinical and biochemical data in FGR and AGA newborns to assess if a mathematical model existed and was capable of identifying these two different conditions in order to identify the variables which had a mathematically consistent biological relevance to fetal growth.
Methods:
Whole villous tissue was collected at birth from FGR (N = 20) and AGA neonates (N = 28). Total RNA was extracted, reverse transcribed and then real-time quantitative (TaqMan) RT-PCR was performed to quantify cDNA for IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IL-6. The corresponding proteins with TNF-&#945; in addition were assayed in placental lysates using specific kits. The data were analysed using Artificial Neural Networks (supervised networks), and principal component analysis and connectivity map.
Results:
The IGF system and IL-6 allowed to predict FGR in approximately 92% of the cases and AGA in 85% of the cases with a low number of errors. IGF-II, IGFBP-2, and IL-6 content in the placental lysates were the most important factors connected with FGR. The condition of being FGR was connected mainly with the IGF-II placental content, and the latter with IL-6 and IGFBP-2 concentrations in placental lysates.
Conclusion:
These results suggest that further research in humans should focus on these biochemical data. Furthermore, this study offered a critical revision of previous studies. The understanding of this system biology is relevant to the development of future therapeutical interventions possibly aiming at reducing IL-6 and IGFBP-2 concentrations preserving IGF bioactivity in both placenta and fetus.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/24</link>		
			<dc:creator>Maria E Street, Enzo Grossi, Cecilia Volta, Elena Faleschini and Sergio Bernasconi</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:24</dc:source>
			<dc:subject>Number of accesses: 522</dc:subject>
			<dc:date>2008-06-17</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-24</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/7/36">
            
            <title>The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study</title>
			<description>Background:
Recently, hyperbaric oxygen therapy (HBOT) has increased in popularity as a treatment for autism. Numerous studies document oxidative stress and inflammation in individuals with autism; both of these conditions have demonstrated improvement with HBOT, along with enhancement of neurological function and cognitive performance. In this study, children with autism were treated with HBOT at atmospheric pressures and oxygen concentrations in current use for this condition. Changes in markers of oxidative stress and inflammation were measured. The children were evaluated to determine clinical effects and safety.
Methods:
Eighteen children with autism, ages 3&#8211;16 years, underwent 40 hyperbaric sessions of 45 minutes duration each at either 1.5 atmospheres (atm) and 100% oxygen, or at 1.3 atm and 24% oxygen. Measurements of C-reactive protein (CRP) and markers of oxidative stress, including plasma oxidized glutathione (GSSG), were assessed by fasting blood draws collected before and after the 40 treatments. Changes in clinical symptoms, as rated by parents, were also assessed. The children were closely monitored for potential adverse effects.
Results:
At the endpoint of 40 hyperbaric sessions, neither group demonstrated statistically significant changes in mean plasma GSSG levels, indicating intracellular oxidative stress appears unaffected by either regimen. A trend towards improvement in mean CRP was present in both groups; the largest improvements were observed in children with initially higher elevations in CRP. When all 18 children were pooled, a significant improvement in CRP was found (p = 0.021). Pre- and post-parental observations indicated statistically significant improvements in both groups, including motivation, speech, and cognitive awareness (p &lt; 0.05). No major adverse events were observed.
Conclusion:
In this prospective pilot study of children with autism, HBOT at a maximum pressure of 1.5 atm with up to 100% oxygen was safe and well tolerated. HBOT did not appreciably worsen oxidative stress and significantly decreased inflammation as measured by CRP levels. Parental observations support anecdotal accounts of improvement in several domains of autism. However, since this was an open-label study, definitive statements regarding the efficacy of HBOT for the treatment of individuals with autism must await results from double-blind, controlled trials.Trial Registrationclinicaltrials.gov NCT00324909</description>
			<link>http://www.biomedcentral.com/1471-2431/7/36</link>		
			<dc:creator>Daniel A Rossignol, Lanier W Rossignol, S Jill James, Stepan Melnyk and Elizabeth Mumper</dc:creator>
			<dc:source>BMC Pediatrics 2007, 7:36</dc:source>
			<dc:subject>Number of accesses: 406</dc:subject>
			<dc:date>2007-11-16</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-7-36</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>36</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/17">
            
            <title>The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: A randomised controlled trial</title>
			<description>Background:
A hypoxic-ischaemic insult occurring around the time of birth may result in an encephalopathic state characterised by the need for resuscitation at birth, neurological depression, seizures and electroencephalographic abnormalities. There is an increasing risk of death or neurodevelopmental abnormalities with more severe encephalopathy. Current management consists of maintaining physiological parameters within the normal range and treating seizures with anticonvulsants.Studies in adult and newborn animals have shown that a reduction of body temperature of 3&#8211;4&#176;C after cerebral insults is associated with improved histological and behavioural outcome. Pilot studies in infants with encephalopathy of head cooling combined with mild whole body hypothermia and of moderate whole body cooling to 33.5&#176;C have been reported. No complications were noted but the group sizes were too small to evaluate benefit.Methods/DesignTOBY is a multi-centre, prospective, randomised study of term infants after perinatal asphyxia comparing those allocated to "intensive care plus total body cooling for 72 hours" with those allocated to "intensive care without cooling".Full-term infants will be randomised within 6 hours of birth to either a control group with the rectal temperature kept at 37 +/- 0.2&#176;C or to whole body cooling, with rectal temperature kept at 33&#8211;34&#176;C for 72 hours. Term infants showing signs of moderate or severe encephalopathy +/- seizures have their eligibility confirmed by cerebral function monitoring. Outcomes will be assessed at 18 months of age using neurological and neurodevelopmental testing methods.Sample sizeAt least 236 infants would be needed to demonstrate a 30% reduction in the relative risk of mortality or serious disability at 18 months.Recruitment was ahead of target by seven months and approvals were obtained allowing recruitment to continue to the end of the planned recruitment phase. 325 infants were recruited.Primary outcomeCombined rate of mortality and severe neurodevelopmental impairment in survivors at 18 months of age. Neurodevelopmental impairment will be defined as any of:&#8226; Bayley mental developmental scale score less than 70&#8226; Gross Motor Function Classification System Levels III &#8211; V&#8226; Bilateral cortical visual impairmentsTrial RegistrationCurrent Controlled Trials ISRCTN89547571</description>
			<link>http://www.biomedcentral.com/1471-2431/8/17</link>		
			<dc:creator>Dennis Azzopardi, Peter Brocklehurst, David Edwards, Henry Halliday, Malcolm Levene, Marianne Thoresen, Andrew Whitelaw and The TOBY Study Group</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:17</dc:source>
			<dc:subject>Number of accesses: 369</dc:subject>
			<dc:date>2008-04-30</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-17</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/16">
            
            <title>Anthropometric surrogates to identify low birth weight Nepalese newborns: a hospital-based study</title>
			<description>Background:
In Nepal, more than 90% of the deliveries take place at home where birth weight is often not recorded. In developing countries, low birth weight (LBW, &lt;2500 grams) accounts for 60&#8211;80% of neonatal deaths. Early identification and referral of LBW babies for extra essential newborn care is vital in preventing neonatal deaths. Studies carried out in different populations have suggested that the use of newborn anthropometric surrogates of birth weight may be a simple and reliable method to identify LBW babies in a home setting. However, a reliable anthropometric surrogate to identify LBW babies and its cut-off point is not known for Nepalese newborns.
Methods:
A cross-sectional study was carried out in Western Regional Hospital, Pokhara between April and June, 2006. All consecutive full-term, singleton, live born babies were included. To ensure reliability and avoid inter-observer bias one of the investigators weighed all the newborns and carried out anthropometric measurements within 24 hours after birth. Circumferences of head, chest, mid-upper arm, thigh and calf were measured according to standard techniques. Non-parametric receiver operating characteristic (ROC) curve analyses were carried out using bootstrap to calculate 95% confidence intervals of areas under the curve (AUC). The cut-points with lowest total misclassification rate were chosen to identify LBW babies.
Results:
Out of 400 newborns studied, 204 (51%) were males and 196 (49%) were females. The mean birth weight was 3029 &#177; 438 grams and 34 (8.5%) newborns were LBW. By ROC-AUC analyses, head circumference (AUC = 0.89, 95% CI 0.85 to 0.93) and chest circumference (AUC = 0.86, 95% CI 0.80 to 0.91) were identified as the optimal surrogate indicators of LBW babies. The optimal cut-points for head circumference and chest circumference to identify LBW newborns were &#8805; 33.5 cm and &#8805; 30.8 cm respectively.
Conclusion:
Head and chest circumferences were the best anthropometric surrogates of LBW among Nepalese newborns. Further studies are needed in the field to cross-validate our results.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/16</link>		
			<dc:creator>Chandrashekhar T Sreeramareddy, Neena Chuni, Rajkumar Patil, Dela Singh and Brishna Shakya</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:16</dc:source>
			<dc:subject>Number of accesses: 368</dc:subject>
			<dc:date>2008-04-25</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-16</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2431/8/20">
            
            <title>Oxidative stress in children late after Kawasaki disease: relationship with carotid atherosclerosis and stiffness</title>
			<description>Background:
Persistent arterial dysfunction in patients with a history of Kawasaki disease (KD) and an integral role of oxidative stress in the development of cardiovascular disease are increasingly recognized. We sought to test the hypothesis that oxidative stress is increased in KD patients and related to carotid atherosclerotic changes and stiffness.
Methods:
We compared the serum levels of oxidative stress biomarkers, carotid intima-media thickness (IMT), and carotid stiffness index among KD patients with coronary aneurysms (n = 32), those without coronary complications (n = 19), and controls (n = 32).
Results:
Compared with controls, patients with coronary aneurysms had significantly higher serum levels of malonaldehyde (2.62 &#177; 0.12 &#956;M vs 2.22 &#177; 0.07 &#956;M, p = 0.014) and hydroperoxides (26.50 &#177; 1.13 &#956;M vs 22.50 &#177; 0.62 &#956;M, p = 0.008). A linear trend of the magnitude of oxidative stress in relation to inflammatory damage was observed for malonaldehyde (p = 0.018) and hydroperoxides (p = 0.014) levels. Serum malonaldehyde and hydroperoxide levels correlated positively with carotid IMT (p &lt; 0.001 and p = 0.034, respectively) and stiffness index (p = 0.001 and p = 0.021, respectively). Multiple linear regression analysis identified serum malonaldehyde level as a significant determinant of carotid IMT (&#946; = 0.31, p = 0.006) and stiffness (&#946; = 0.27, p = 0.008).
Conclusion:
Our findings suggest oxidative stress is increased in KD patients with coronary aneurysms and is associated with carotid intima-media thickening and stiffening.</description>
			<link>http://www.biomedcentral.com/1471-2431/8/20</link>		
			<dc:creator>Yiu-fai Cheung, Karmin O, Connie WH Woo, Stephanie Armstrong, Yaw L Siow, Pak-cheong Chow and Eddie WY Cheung</dc:creator>
			<dc:source>BMC Pediatrics 2008, 8:20</dc:source>
			<dc:subject>Number of accesses: 361</dc:subject>
			<dc:date>2008-05-08</dc:date>
			<dc:identifier>doi:10.1186/1471-2431-8-20</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pediatrics</prism:publicationName>
					
			
							
					<prism:issn>1471-2431</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
